Company / Free Cash Flow
Protara Therapeutics, Inc. Free Cash Flow History
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$10.0M
FY2016
5-year range
-$10.0M / -$6.7M
FY2014-FY2016
Trend
-50.6%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$8M to -$10M over the past 2 years.
Based on SEC 10-K filings.
-$10M in FY2016.
Declined from -$8M to -$10M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2016, free cash flow decreased 50.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.74 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2016 | -$10.0M | -50.6% |
| FY2015 | -$6.7M | +19.7% |
| FY2014 | -$8.3M | - |
As of FY2016 · SEC 10-K Annual Filings · Last checked Jun 28, 2026